Liaoning Cheng Da Co., Ltd.

600739

CNE000000LY3

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
10.3 ^CNY	+4.67%		+1.78%	-12.56%

Apr. 26	Liaoning Cheng Da Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Liaoning Cheng Da Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	CI

Liaoning Cheng Da Co., Ltd.(XSSC:600739) added to S&P Global BMI Index

September 18, 2023 at 12:00 am EDT

Latest news about Liaoning Cheng Da Co., Ltd.

Liaoning Cheng Da Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 26	CI
Liaoning Cheng Da Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Liaoning Cheng Da Co., Ltd.(XSSC:600739) added to S&P Global BMI Index	23-09-18	CI
Liaoning Cheng Da Co., Ltd.(XSSC:600739) added to FTSE All-World Index	23-09-18	CI
Liaoning Cheng Da Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Liaoning Cheng Da Co., Ltd.(SHSE:600739) added to Shanghai Stock Exchange Health Care Sector Index	23-06-12	CI
Liaoning Cheng Da Gets Regulatory Nod to Issue 5 Billion Yuan Ultra-Short Term Bonds	23-06-02	MT
Tranche Update on Liaoning Cheng Da Co., Ltd.'s Equity Buyback Plan announced on July 27, 2022.	23-06-01	CI
Liaoning Cheng Da Co., Ltd.'s Equity Buyback announced on July 27, 2022 has expired with 7,393,888 shares, representing 0.48% for CNY 100.05 million.	23-05-30	CI
Liaoning Cheng Da Unit Under Investigation For Illegal Land Use	23-05-30	MT
Liaoning Cheng Da Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Liaoning Cheng Da Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14	CI
Tranche Update on Liaoning Cheng Da Co., Ltd.'s Equity Buyback Plan announced on July 27, 2022.	23-04-03	CI
Tranche Update on Liaoning Cheng Da Co., Ltd.'s Equity Buyback Plan announced on July 27, 2022.	23-01-03	CI
Liaoning Cheng Da Issues 600 Million Yuan Bonds	22-12-28	MT
Liaoning Cheng Da Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Tranche Update on Liaoning Cheng Da Co., Ltd.'s Equity Buyback Plan announced on July 27, 2022.	22-10-10	CI
Liaoning Cheng Da Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-30	CI
Liaoning Cheng Da Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares, under the authorization approved on May 31, 2022.	22-07-26	CI
Liaoning Cheng Da Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI
Liaoning Cheng Da Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-21	CI
Liaoning Cheng Da Co., Ltd.(XSSC:600739) dropped from S&P Global BMI Index	21-12-20	CI
Liaoning Cheng Da Co., Ltd.(XSSC:600739) dropped from FTSE All-World Index	21-12-13	CI
Liaoning Cheng Da Co., Ltd.(SHSE:600739) dropped from SSE 180 Index	21-12-10	CI
Liaoning Cheng Da Co., Ltd.(SHSE:600739) dropped from Shanghai Stock Exchange 180 Value Index	21-12-10	CI

Chart Liaoning Cheng Da Co., Ltd.

Duration

Period

More charts

Liaoning Chengda Co., Ltd. is a diversified group organized around six sectors of activity: - retail distribution of clothes; - consumer goods trading: chemical products, oils for food, textile products, electronic products, construction materials, health products, etc.; - detention and operating of drugstores; - development of vaccines; - development of energetic projects: coalmines operating, production petrol, etc.; - financial services. Net sales are distributed geographically as follows: China (92.1%), Asia (4.9%), Americas (2.5%), Europe (0.2%), Africa (0.2%) and Oceania (0.1%).

Sector

Pharmaceuticals

Calendar

2024-04-29 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LIAONING CHENG DA CO., LTD.	-12.56%	2.16B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B